Share on LinkedInShare on LinkedIn

ARTICLE · 14 JULY 2013

Federal Circuit Finds Wyeth Restenosis Claims Invalid As Not Enabled

In "Wyeth v. Abbott Laboratories", the Federal Circuit affirmed the district court’s decision that the claims at issue are invalid for failing to satisfy the enablement requirement of 35 USC § 112.

United StatesIntellectual Property

In Wyeth v. Abbott Laboratories, the Federal Circuit affirmed the district court's decision that the claims at issue are invalid for failing to satisfy the enablement requirement of 35 USC § 112. The court took only 10 pages to explain why a specification that describes one specific compound did not enable claims encompassing tens of thousands of compounds.

The Patents at Issue

The patents at issue are U.S. Patent 5,516,781 and U.S. Patent 5,563,146, which are based on the same specification. As summarized by the Federal Circuit, the patents "relate to the use of rapamycin for the treatment and prevention of restenosis, which is the renarrowing of an artery." The claims at issue recite methods of treating or preventing restenosis by "administering an antirestenosis effective amount of rapamycin" to a mammal."

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from